Tuesday 13 October 2026 Export ALT’s income statement to Excel — free account

Altimmune, Inc.

Altimmune, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41,000.00, up 105.0% from fiscal 2024. In the quarter to June 2026, revenue grew 520.0%, EPS grew 55.6%, free cash flow fell 25.3% and total debt rose 142.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

2.49 0.07 −2.73%

Follow ALT

Alert me

Market cap: $498.0M
P/E: 0.0×
Fwd P/E: −3.9×
Dividend yield: —
F-score: 4/9
Altman Z: 0.23
Beneish M: −3.17
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.37

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	3	2	—	2	3	—	—	—	1	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.97%

Capital & Financial Ratios $m

Market Cap 497.96

Revenue 0.05

Net Income (91.76)

Free Cash Flow (76.56)

Net Debt (291.58)

Current Ratio 26.78

Debt/Equity 0.07

P/E ratio 0.00

Fwd P/E (3.93)

P/S ratio 10,320.35

P/B ratio 1.00

Past 5Y EPS Growth —

This Y EPS Growth 41.80%

Next Y EPS Growth (9.21%)

Next Y revenue growth 6,148.78%

Next 5Y EPS Growth 14.25%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 85.77%

10-year low 10-year high

P/B against its own 10 years 41.97%

10-year low 10-year high

EV/Sales against its own 10 years 78.30%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	2.91	2.91
2016	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	198	132	273	326
Receivables	5	3	2	3
Inventory	—	—	—	—
Other	—	—	—	—
	210	137	278	335

	2023	2024	2025	Q'26
Payables	2	0	3	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	12	10	15	13

Compound Annual Growth %

	10y	5y	3y
Sales	(42.64%)	(65.33%)	0.00%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	29.74%	(0.09%)	6.67%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	0	0	0	0	0
’24	0	0	0	0	0
’23	0	0	0	0	0
’22	0	0	0	0	0
’21	1	0	0	3	4
’20	2	1	3	2	8

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(21)	(24)	—	—	—
’25	(17)	(19)	(12)	(19)	(68)
’24	(16)	(18)	(27)	(18)	(80)
’23	(19)	(19)	(20)	(17)	(76)
’22	(14)	(17)	(15)	(17)	(63)
’21	(20)	(19)	(18)	(22)	(78)
’20	(4)	(7)	(10)	(13)	(34)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(21)	(24)	—	—	—
’25	(17)	(19)	(12)	(19)	(68)
’24	(16)	(18)	(27)	(18)	(80)
’23	(19)	(19)	(20)	(17)	(76)
’22	(14)	(17)	(15)	(17)	(63)
’21	(24)	(27)	(18)	(22)	(91)
’20	(4)	(7)	(10)	(13)	(35)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.18)	(0.12)	—	—	—
’25	(0.26)	(0.27)	(0.21)	(0.27)	(1.00)
’24	(0.34)	(0.35)	(0.32)	(0.33)	(1.34)
’23	(0.40)	(0.32)	(0.39)	(0.54)	(1.66)
’22	(0.44)	(0.42)	(0.48)	(0.43)	(1.81)
’21	(0.38)	(0.60)	(0.81)	(0.57)	(2.35)
’20	(0.26)	(0.94)	(0.54)	(0.17)	(1.91)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	45.30	1.70	1.51	1.60	8.10	3.83	2.09	5.28	2.90	Analyst estimates 2026–2028 Powerpack
	High	—	137.70	66.00	5.94	35.10	24.61	23.49	17.17	14.84	7.83
People
People	Employees	13	30	27	25	43	47	52	59	59	57
	Revenue/emp, $m	0.25	0.36	0.38	0.23	0.19	0.09	0.00	0.01	0.00	0.00
Income, $m
Income, $m	Revenue	3	11	10	6	8	4	0	0	0	0
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(11)	(52)	(45)	(21)	(54)	(97)	(85)	(88)	(95)	(89)
	EBT margin, %	(342.59)	(484.84)	(438.68)	(354.72)	(665.38)	(2,201.59)	124,867.65	(20,762.21)	(475,295.00)	(216,521.95)
	Net income	(11)	(46)	(39)	(21)	(49)	(97)	(85)	(88)	(95)	(88)
	Depreciation	0	36	25	0	0	1	0	10	(4)	(2)
Per share, $
Per share, $	Revenue	14.06	24.86	3.69	0.44	0.32	0.11	0.00	0.01	0.00	0.00
	Earnings	(48.17)	(120.42)	(15.16)	(1.60)	(1.91)	(2.35)	(1.81)	(1.66)	(1.34)	(1.00)
	Cash flow	(27.60)	(46.80)	(3.35)	(0.73)	(1.34)	(1.90)	(1.33)	(1.42)	(1.12)	(0.77)
	Capex	(0.96)	(0.37)	(0.36)	0.00	(0.01)	(0.30)	0.00	0.00	0.00	0.00
	Free cash flow	(28.56)	(47.17)	(3.71)	(0.73)	(1.35)	(2.19)	(1.34)	(1.42)	(1.12)	(0.77)
	Book value	139.91	91.22	17.24	3.47	8.81	4.82	3.95	3.65	1.74	2.55
	Shares, m	0	0	3	13	26	41	47	53	71	88
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	2.41	0.56	4.28	35.33	85.75	0.00	1,314.92	25,596.73	6,914.26
	P/B	0.00	0.66	0.12	0.55	1.28	1.90	3.96	2.89	4.15	1.41
	EV/Sales	(0.81)	1.32	(2.69)	(1.86)	9.15	42.88	(8,079.20)	851.59	19,023.93	1,717.80
	EV/FCF	0.40	(0.70)	2.68	1.12	(2.16)	(2.09)	(8.73)	(4.77)	(4.75)	(1.17)
Cash, $m
Cash, $m	Operating cash flow	(6)	(20)	(9)	(10)	(34)	(78)	(63)	(76)	(80)	(68)
	Capex	0	0	(1)	0	0	(12)	0	0	—	0
	Free cash flow	(7)	(20)	(10)	(10)	(35)	(91)	(63)	(76)	(80)	(68)
Balance, $m
Balance, $m	Working capital	(1)	20	35	35	218	186	176	197	127	263
	Total debt	0	0	1	1	1	1	1	—	—	34
	Net debt	(3)	(12)	(34)	(36)	(214)	(189)	(184)	(198)	(132)	(239)
	Shareholders’ equity	32	39	48	46	226	199	185	194	124	225
Returns, %
Returns, %	ROA	(39.32)	(101.26)	(72.13)	(38.55)	(32.79)	(41.85)	(39.79)	(42.36)	(54.33)	(42.03)
	ROIC	(23.62)	(120.07)	(185.13)	(131.45)	(300.78)	(610.37)	(5,217.65)	0.00	0.00	0.00
	ROE	(46.90)	(143.46)	(96.86)	(44.70)	(36.14)	(45.69)	(44.07)	(46.63)	(59.86)	(50.57)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PROK ProKidney Corp.	$526.0M	— (loss-making)	— (loss-making)	−32.13% (below 0%: shrinking)	n/m	−28.03% (below 0%: shrinking)	100.00%	(32,248.67%)	Compare
CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR	$524.8M	— (loss-making)	— (loss-making)	−7.53% (below 0%: shrinking)	n/m	−31.52% (below 0%: shrinking)	0.00%	0.00%	Compare
OCS Oculis Holding AG	$514.9M	— (loss-making)	— (loss-making)	+23.96% (above 0%: growing)	n/m	−10.40% (below 0%: shrinking)	100.00%	(7,603.42%)	Compare
ALT Altimmune, Inc.	$507.7M	— (loss-making)	— (loss-making)	+520.00% (above 0%: growing)	n/m	−25.27% (below 0%: shrinking)	100.00%	0.00%
ALLO Allogene Therapeutics, Inc.	$504.4M	— (loss-making)	— (loss-making)	+20,990.91% (above 0%: growing)	n/m	+17.73% (above 0%: growing)	100.00%	(1,011.21%)	Compare
CTNM Contineum Therapeutics, Inc.	$503.4M	— (loss-making)	—	—	n/m	+26.73% (above 0%: growing)	100.00%	0.00%	Compare
ARVN Arvinas, Inc.	$499.6M	57.3×	— (loss-making)	+1,014.73% (above 0%: growing)	n/m	+49.79% (above 0%: growing)	96.40%	65.72%	Compare
EPRX Eupraxia Pharmaceuticals Inc.	$491.7M	— (loss-making)	—	—	n/m	−56.41% (below 0%: shrinking)	—	0.00%	Compare
MPLT MapLight Therapeutics, Inc.	$490.7M	— (loss-making)	—	—	n/m	−31.91% (below 0%: shrinking)	—	0.00%	Compare
Median of peers	$503.9M	—	—	+23.96%	—	−19.21%	100.00%	0.00%

All 614 Biotechnology stocks →

Altimmune, Inc. (ALT) key facts

Strength: Altimmune, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41,000.00, up 105.0% from fiscal 2024.
Altimmune, Inc. (ALT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 12, 2026, ALT traded at $2.56, a market capitalization of $498.0 million.
Return on equity was −50.6% and debt-to-equity 0.07.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 0.23 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.